🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Owlet shares maintain Buy rating on accelerated growth potential

EditorNatashya Angelica
Published 06/07/2024, 11:10 PM
OWLT
-

On Friday, TD Cowen reaffirmed its confidence in Owlet Inc. (NYSE:OWLT), maintaining a Buy rating and a $15.00 price target for the company's shares. The endorsement comes as the firm recognizes Owlet's potential for accelerated growth in the near future.

This optimism is attributed to several factors, including the anticipated increase in sales of Owlet's Dream Sock in the U.S. and European markets, the expected success of BabySat, and the development of a comprehensive baby care application.

The firm's assessment points to Owlet's significant advances over potential market competitors, citing the company's extensive clinical research and strong retail partnerships. According to the firm, these elements are key in fostering unique consumer awareness and trust in Owlet's products.

Owlet, known for its health technology products designed for infants, has been focusing on expanding its product lineup. The Dream Sock, which monitors infants' vital signs, and BabySat, another product in Owlet's range, are central to the company's strategy for growth. Moreover, the development of a multi-functional baby care application is expected to further consolidate Owlet's position in the market.

The firm's reiterated Buy rating and price target reflect a belief in Owlet's strategic direction and its ability to outpace the competition. Owlet's commitment to clinical research and the establishment of robust retail relationships are seen as pivotal to the company's continued success and consumer confidence.

Investors and market watchers will be keeping a close eye on Owlet's performance as it strives to meet these growth expectations and solidify its market position through its innovative product offerings and technological advancements.

In other recent news, Owlet, Inc. reported significant financial growth in its first quarter of 2024. The company saw a 48% increase in gross billings to $18.4 million and a 37% increase in net revenue to $14.8 million year-over-year.

The gross margin improved to 44.4% in Q1 2024, up from 38.7% in the previous year, and net income for Q1 was $3.3 million, a notable turnaround from a loss of $11.9 million in Q1 2023. Owlet also mentioned the recent FDA and CE Medical authorization in Europe for their infant health monitoring products.

In another development, Owlet's Dream Sock product has received UKCA certification, enabling its sale in the United Kingdom. This certification allows Owlet to extend its reach in the European market, which sees over 3.8 million births annually.

The Dream Sock monitors oxygen saturation and pulse rate in healthy infants and provides sleep insights to parents. Owlet plans to launch the Dream Sock at major retailers in the UK, Germany, and France in the coming months.

These developments are part of Owlet's recent achievements and growth strategy, which includes the adoption of its Dream Sock product, expansion into medical distribution channels with BabySat, and the launch of a new subscription service.

InvestingPro Insights

Recent analysis from InvestingPro provides a deeper dive into Owlet Inc.'s financial health and market performance. Notably, Owlet holds more cash than debt on its balance sheet, which is a positive sign for investors looking for financial stability in the companies they invest in. However, it's important to note that the company has been rapidly burning through cash, which could raise concerns about long-term sustainability.

On the market front, Owlet has experienced a significant return over the last week, with a 22.49% price total return, reflecting a positive short-term investor sentiment. This might interest traders looking for momentum plays. The stock, however, has shown quite volatile price movements, which could be a point of caution for risk-averse investors.

From a valuation perspective, Owlet's market capitalization stands at $41.29M, and it currently has a negative P/E ratio of -1.65, indicating that the company is not profitable as of the last twelve months ending Q1 2024. This aligns with the InvestingPro Tip that analysts do not anticipate Owlet will be profitable this year. Despite these challenges, the stock has yielded a high return over the last year, at 60.63%, which could capture the interest of growth-focused investors.

For those looking to explore further, InvestingPro offers additional tips on Owlet Inc. to help refine investment strategies. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to the full range of insights and metrics that InvestingPro provides. There are 5 more InvestingPro Tips available that could provide valuable guidance in your investment decision-making process.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.